💊 Obat A-Z 🧬 Target 🛠 Alat 📚 Panduan
Semua Obat Kelas Obat Area Terapeutik Efek Samping
Panduan Glosarium Linimasa
Perbandingan Perjalanan Obat Famili Obat
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Niraparib

CHEMBL1094636 Phase 4 Disetujui Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
320.4 g/mol
LogP
2.2
Phase
4

A PARP inhibitor that blocks a DNA repair enzyme, causing cancer cells with certain genetic mutations to die.

Berat Molekul

320,4000 g/mol

LogP

2,20

TPSA

72,90 Ų

Lipinski RO5

Lulus

Area Terapeutik

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Melanoma Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

Mekanisme Kerja

Inhibits poly(ADP-ribose) polymerase (PARP) enzymes involved in DNA single-strand break repair, exploiting homologous recombination deficiency in cancer cells to cause synthetic lethality.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Inhibits poly(ADP-ribose) polymerase (PARP) enzymes involved in DNA single-strand break repair, exploiting homologous recombination deficiency in cancer cells to cause synthetic lethality.

Struktur 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12

                

                

                
                

                    
InChI

                    
InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C19H20N4O

                    

                    
                    

                        
HBD / HBA

                        
2 / 3

                    

                    
                    

                        
Ikatan yang Dapat Dirotasi

                        
3

                    

                    
                    
                    

                        
Atom Berat

                        
24

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Pertanyaan yang Sering Diajukan

                

                    
                    

                        
                        

                            
A PARP inhibitor that blocks a DNA repair enzyme, causing cancer cells with certain genetic mutations to die.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits poly(ADP-ribose) polymerase (PARP) enzymes involved in DNA single-strand break repair, exploiting homologous recombination deficiency in cancer cells to cause synthetic lethality.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Niraparib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1094636.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 24958200.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Penyangkalan Medis

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.